GM-1111 Reduces Radiation-induced Oral Mucositis in Mice by Targeting Pattern Recognition Receptor-mediated Inflammatory Signaling
Overview
Authors
Affiliations
Purpose: Oral mucositis (OM) is a common, painful side effect of radiation therapy used for the treatment of head and neck cancer (HNC). Activation of the innate immune system upon irradiation has been identified as a key precipitating event of OM. To better understand OM's pathogenesis, we studied pattern recognition receptors (PRRs) and their downstream pro-inflammatory cytokines in a mouse model of radiation-induced OM. We also tested therapeutic efficacy of GM-1111 that targets innate immune system to reduce radiation-induced OM.
Methods And Materials: The pathogenesis of OM was studied in a single X-ray induced mouse model. The severity of OM was measured by visual and microscopical examinations. The irradiation-induced changes of PRRs and their downstream effector cytokine gene expression levels were determined. The efficacy of GM-1111 to reduce OM was tested in single and fractionated irradiation mouse models. The impact of the drug on tumor response to radiation therapy was also tested in a mouse model of human HNC.
Results: Radiation-induced tissue ulcerations were radiation-dosage and -time dependent. The lesions showed selective increases in PRR and pro-inflammatory cytokine gene expression levels. Once daily administration of GM-1111 (≥30 mg/kg, s.c.) significantly reduced the severity and the incidence of OM. The drug had little effect on PRRs but significantly inhibited downstream pro-inflammatory cytokine genes. GM-1111 did not interfere radiation therapy to induce HNC SCC-25 tumor regression. Instead, we observed significant drug-induced tumor regression.
Conclusions: Radiation induces tissue damages. The increased expression levels of PRRs and their downstream pro-inflammatory cytokine genes in the damaged tissues suggest their important contribution to the pathogenesis of OM. Drug GM-1111 that targets these innate immune molecules may be a potential drug candidate as an intervention for OM.
Srivastava R, Muzaffar S, Khan J, Bansal M, Agarwal A, Athar M Sci Rep. 2025; 15(1):6505.
PMID: 39987158 PMC: 11846883. DOI: 10.1038/s41598-024-83513-1.
Pachler K, Lauwers I, Verkaik N, Rovituso M, van der Wal E, Mast H Int J Mol Sci. 2024; 25(13).
PMID: 39000262 PMC: 11241643. DOI: 10.3390/ijms25137157.
The Role of the Innate Immune Response in Oral Mucositis Pathogenesis.
Bowen J, Cross C Int J Mol Sci. 2023; 24(22).
PMID: 38003503 PMC: 10670995. DOI: 10.3390/ijms242216314.
Role of hair follicles in the pathogenesis of arsenical-induced cutaneous damage.
Srivastava R, Wang Y, Khan J, Muzaffar S, Lee M, Weng Z Ann N Y Acad Sci. 2022; 1515(1):168-183.
PMID: 35678766 PMC: 9531897. DOI: 10.1111/nyas.14809.
Shi J, Kanoya R, Tani Y, Ishikawa S, Maeda R, Suzuki S Int J Mol Sci. 2022; 23(9).
PMID: 35563446 PMC: 9102160. DOI: 10.3390/ijms23095055.